Edwards Lifesciences (EW) Research & Development (2009 - 2026)

Edwards Lifesciences' Research & Development history runs 18 years deep, the most recent figure standing at $263.3 million for Q1 2026.

• On a quarterly basis, Research & Development rose 3.42% year-over-year to $263.3 million in Q1 2026; TTM through Mar 2026 was $1.1 billion, a 3.52% increase from a year earlier, with the FY2025 full-year figure at $1.1 billion, up 2.49% from the prior year.
• Research & Development eased to $263.3 million in Q1 2026 per EW's latest filing, from $267.7 million in the prior quarter.
• Across five years, Research & Development topped out at $280.7 million in Q3 2025 and bottomed at $130.6 million in Q4 2022.
• The 5-year median for Research & Development is $254.6 million (2025), against an average of $248.8 million.
• Across the five-year window, Research & Development slumped 43.9% in 2022 and jumped 85.38% in 2023, its largest moves.
• Year by year, Research & Development stood at $130.6 million in 2022, then jumped by 85.38% to $242.1 million in 2023, then climbed by 11.98% to $271.1 million in 2024, then declined by 1.25% to $267.7 million in 2025, then dropped by 1.64% to $263.3 million in 2026.
• Per Business Quant, the three latest EW Research & Development figures stand at $263.3 million (Q1 2026), $267.7 million (Q4 2025), and $280.7 million (Q3 2025).